Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Incyte Corporation
Incyte Corporation
Zhengzhou University
Beijing Tongren Hospital
University of Maryland, Baltimore
Memorial Sloan Kettering Cancer Center